Overview
Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy Participants
Status:
Recruiting
Recruiting
Trial end date:
2022-04-01
2022-04-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This is a single-center, in-house, open-label, crossover study in 15 healthy participants.Phase:
Phase 1Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Alumis IncTreatments:
Rabeprazole
Criteria
Inclusion Criteria:- Healthy Men and woman age 18-60
- Able to provide written informed consent
- Females can not be pregnant or lactating
Exclusion Criteria:
- Prior exposure to ESK-001
- History of malignancy within the last 10 years
- Positive for HIV, Hepatitis B or C
- History of tuberculosis
- Positive test for alcohol or drugs